Analystreport

CTI BioPharma Corp (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Cann. They now have a $4.00 price target on the stock.

CTI BioPharma Corp.  (CTIC) 
Last cti biopharma corp. earnings: 11/1 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ctibiopharma.com